Similar articles

• [Bisphosphonates (BP) and osteonecrosis of the jaws; should administration of BP be discontinued at the early phase?].

  Urade M. Urade M. Clin Calcium. 2010 Nov;20(11):1740-3. Clin Calcium. 2010. PMID: 21066911 Review. Japanese. No abstract available.
• American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws.

  Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. J Oral Maxillofac Surg. 2007 Mar;65(3):369-76. doi: 10.1016/j.joms.2006.11.003. J Oral Maxillofac Surg. 2007. PMID: 17307580 No abstract available.
• Bisphosphonates: a potential threat to your patients.

  Dreiman BB. Dreiman BB. J Indiana Dent Assoc. 2005-2006 Winter;84(4):4-9. J Indiana Dent Assoc. 2005. PMID: 16605211 No abstract available.
• American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

  Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. Ruggiero SL, et al. J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12. doi: 10.1016/j.joms.2009.01.009. J Oral Maxillofac Surg. 2009. PMID: 19371809 No abstract available.
• A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.

  Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. Pazianas M, et al. Clin Ther. 2007 Aug;29(8):1548-58. doi: 10.1016/j.clinthera.2007.08.008. Clin Ther. 2007. PMID: 17919538 Review.